

Scott T. Guenthner M.D.
The Indiana Clinical Trials Center, PC
824 Edwards Drive, Suite 172
Plainfield, Indiana 46168
Phone: (317) 837-6082

PROFESSIONAL EXPERIENCE:

03/2006 – Present	President/CEO/Principle Investigator The Indiana Clinical Trials Center, PC Plainfield, Indiana
7/2002 – Present	Physician/President Dermatologist The Dermatology Center of Indiana, PC Plainfield, Indiana
6/1995 – 8/1995	Research Assistant College of Medicine Student Research Fellowship University of Iowa Iowa City, Iowa
1/1992 – 8/1994	Research Assistant Complement Laboratory University of Iowa Iowa City, Iowa

CERTIFICATION AND LICENSURE:

7/2002	Indiana Medical License #01051021
11/2002 – Present	American Board of Dermatology
03/2009- Present	Good Clinical Practice Certification

HOSPITAL AFFILIATIONS:

7/2002 – Present	Hendricks Regional Health Danville, Indiana
7/2002 – Present	St. Francis Hospitals and Health Services Indianapolis, Indiana
7/2003 – Present	Clarian West Medical Center Avon, Indiana
7/2004 – Present	St. Vincent Hospitals and Health Services Indianapolis, Indiana
10/2005- Present	Community Hospitals Indianapolis, Indiana

EDUCATION:

Graduated 5/1998 Doctor of Medicine
University of Iowa
Iowa City, Iowa

Graduated 5/1994 Bachelor of Science with Highest Distinction
Psychology
University of Iowa
Iowa City, Iowa

Honors:

Medical: President, Alpha Omega Alpha, Iowa Chapter, 1997
The Hancher-Finkbine Medallion, 1998

Undergraduate : Phi Beta Kappa, Junior Inductee, 1993
Cumulative GPA 4.0
University of Iowa Collegiate Scholar, 1994
Omicron Delta Kappa Province XI Leader of the Year, 1993-94

Activities:

Medical : President, Medical Student Ambassador Program, 1996
Medical Student Council, 1995-1998
Student Preceptor, M1 Physical Examination Skills, 1997-1998
Undergraduate: Co-President, Phi Beta Kappa
General Council, Omicron Delta Kappa
Volunteer, Johnson County Big Brothers/Big Sisters Program

POST GRADUATE TRAINING:

7/1999 – 6/2002 Residency
Dermatology
Indiana University
Indianapolis, Indiana

FELLOWSHIPS:

7/1998 – 6/1999 Transitional Internship
St. Vincent Hospital and Health Services
Indianapolis, Indiana

MEMBERSHIPS/COMMITTEES:

7/2002 – Present University of Iowa Alumni Association Board of Directors

PROJECTS:

5/1999 **Indiana University Department of Dermatology**
Skin Cancer Education Project
Coordinated a skin cancer education project in which faculty and residents in the Department of Dermatology educated individuals of the community about melanoma and non-melanoma skin cancers at a local minor league baseball game.

PUBLICATIONS, ABSTRACTS , AND PRESENTATIONS:

Maves, KK, Guenther, ST, et.al.. *Cloning and characterization of the cDNA encoding guinea pig properdin: a comparison of properdin from three species.* Immunology, 86 (3), 475-79, Nov., 1995

Guenther, ST, Hurwitz, RM, Buckel, LJ, and Gray, HR. *Cutaneous Squamous Cell Carcinomas Consistently Show Histologic Evidence of In-Situ Changes: A Clinical-Pathological Correlation.* Journal of the American Academy of Dermatology, 41(3), 443-48, Sept., 1999.

Guenther, ST, Hurwitz, RM, Buckel, LJ, and Gray, HR. *Cutaneous Squamous Cell Carcinomas Consistently Show Histologic Evidence of In-Situ Changes: A Clinical-Pathological Correlation.* Abstract, Journal of Cutaneous Pathology, 26 (9), 465, Oct., 1999.

Guenther, ST, Hurwitz, RM, Buckel, LJ, and Gray, HR. *Cutaneous Squamous Cell Carcinomas Consistently Show Histologic Evidence of In-Situ Changes: A Clinical-Pathological Correlation.* Poster Presentation. The American Society of Dermatopathology Annual Meeting, San Diego, CA, Nov 4-7, 1999.

Guenther, ST, Draft, KS, and Hood, AF. Virtual Dermatology Case, Indiana University Department of Dermatology, May, 2000.

Piliang MP, Guenther ST, Treadwell PA. *Abnormal hair growth in a child with atopy.* Archives of Dermatology. 137(11), 1521-6, Nov, 2001.

Jungers EA, Guenther ST, Farmer ER, Perkins SM. *A skin cancer education initiative at a professional baseball game and results of a skin cancer survey.* Int J Dermatol. 2003 Jul; 42(7): 524-9.

Schaefer C, Cappelleri JC, Cole J, Guenther S, Fowler J, Johnson S, Mamolo C. *Burden-of-Illness in Moderate-to-Severe Psoriasis Subjects Seeking Treatment: An Overall Descriptive Assessment* (2013).

Pariser, D., McConnehey, D., Matheson, R., Kempers, S., Guenther, S., Bukhalo, M. *A Phase 2 Study of Photodynamic Therapy (PDT) with Aminolevulinic Acid HCl (ALA) 20% Topical Solution + Blue Light vs ALA Topical Solution Vehicle + Blue Light Using Spot and Broad Area Application and Incubation Times of 1, 2 & 3 Hours for the Treatment of Multiple Actinic Keratoses (AK) on the Face or Scalp.* Presented at the 71st Annual American Academy of Dermatology Meeting March 2013.

CLINICAL TRIAL EXPERIENCE:

3/2006 – 08/2006	COBRA Trial, Phase IV Trial of Clobex Spray for the Treatment of Plaque Psoriasis
6/2006-12/2009	Phase IV Study of Raptiva Safety (RESPONSE)
8/2007-3/2008	Phase III Study of Raptiva in TNF- Alpha Biologic Failures

10/2007-12/2007	Phase III Study of Brand vs Generic Benzaclin Gel Efficacy and Safety
1/2008-10/2008	Phase III Study of Brand vs. Generic Duac Gel Efficacy and Safety
3/2008-2/2010	Phase III Study of Raptiva Effectiveness for Scalp Psoriasis
9/2008-1/2009	Phase III Study of Brand vs. Generic Aldara Cream for the Treatment of Actinic Keratosis Efficacy and Safety
10/2008-4/2009	Phase III Study of Ingenol Mebutate Gel vs Placebo for the Treatment of Actinic Keratosis Efficacy and Safety
12/2008- 6/2009	Phase III Study of ABT-874 vs Etanercept vs Placebo for the Treatment of Moderate to Severe Plaque Psoriasis Efficacy and Safety
12/2008-1/2009	Phase III Study of Brand vs Generic Protopic 0.1% for the Treatment of Atopic Dermatitis
2/2009- 9/2009	Phase III Study of Brand vs. Generic Aldara Cream for the Treatment of Actinic Keratosis Efficacy and Safety
5/2009-11/2009	Phase IV Study, Open-label, 12-week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction with Oracea (doxycycline, USP) Capsules 40 mg (30mg immediate release and 10 mg delayed release beads) as Monotherapy or as Add-on Therapy to Existing Topical Regimens for the Treatment of Rosacea
6/2009-1/2010	A Phase III, Multi-Center, Randomized, Parallel Group, Double-Blind, Vehicle Controlled Study to evaluate the Efficacy and Safety of PEP005 Gel, 0.015% in Patients with Actinic Keratosis ON the Head (Face or Scalp)
3/2006– 04/2013	Phase IV Five year Study of Enbrel Safety (OBSERVE)
1/2009-06/2012	Phase III Study of Alitretinoin vs Placebo for the Treatment of Chronic Hand Eczema Efficacy and Safety
5/2009-02/2012	A Phase III, Multi-Center, Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study with ABT-874
8/2009-12/2010	A 12 Month, Long Term Follow-up Study of Patients with Actinic Keratosis on the Head (face or Scalp) who have Completed the Day 57 in Studies PEP005-016 or PEP005-025
9/2009- 07/2011	Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in patient with severe recalcitrant nodular acne
08/2010-12/2011	Phase III, A Double-Blind, Vehicle Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate The Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients with Moderate to Severe Plaque Psoriasis

09/2010-01/2012	Phase II, Multicenter, Randomized, Double-Blind, Dose-Ranging Study to Evaluate IDP-107 Versus Placebo in the Treatment of Severe Acne Vulgaris with Nodules
10-2010-07/2011	Phase III, A National, Multi-center, Propective, Randomized, Double-Blind, 4-arm, Parallel Group, 8-week Study in Subjects with Psoriasis Vulgaris on the Non-Scalp Regions of the Body (trunk or limbs)
10-2010- 07/2011	Phase III, A Randomized, Controlled Evaluation of the Safety and Efficacy of a Topical Treatment for Moderate- Severe Facial Acne Vulgaris
03/2011-01/2012	A Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream 3.75% And Zyclara (Imiquimod) Cream 3.75% In Subjects with Actinic Keratoses
06/2011-02/2012	A Multicenter, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% to Epiduo and Both Active Treatments to Placebo in the Treatment of Mild to severe Acne Vulgaris
09/2011-04/2012	A Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Study Comparing Metronidazole Topical Gel 1% to Metrogel 1% in the Treatment of Moderate to Severe Rosacea
12/2011- 07/2012	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Rosacea-Specific Inflammatory Biochemical markers in the Skin of Adults with Papulopustular Rosacea Treated with Daily Doxycycline 40 mg (30 mg Immediate Release/10mg Delayed Release) capsules
12/2011-12/2012	A Phase II Study of Photodynamic Therapy with Levulun Topical Solution+ BLU light vs. Levulun Topical Solution Vehicle + BLU Light Using Spot and Broad Area Application and Incubation Times of 1,2, and 3 Hours For the Treatment of Multiple Actinic Keratoses on the Face and Scalp
12/2011-08/2012	An Evaluation of the Burden of Illness Among Adults in the United States with Moderate to Severe Plaque Psoriasis
03/2012- 09/2013	Phase 3 Randomized, Double-Blind, 12- week, Vehicle controlled, parallel-group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40- week investigator blinded extension comparing the long- term safety of CD5024 1% cream versus azelaic acid 15% gel
03/2012- 11/2013	A Sequential Treatment Regimen of Cryotherapy and Picato (Ingenol Mebutate) gel, 0.015% Field Therapy Compared to cryotherapy alone for the treatment of Actinic Keratoses on the Face and Scalp
04/2012- 12/2012	A Phase II Study Comparing Treatment with LEO 90100 with Betamethasone Dipropionate in LEO 90100 Vehicle and Calcipotriol in LEO 90100 Vehicle in Subjects with Psoriasis Vulgaris

04/2012- 12/2012	A Phase II Study Comparing Treatment with LEO 90100 with Calcipotriol Plus Betamethasone Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects with Psoriasis Vulgaris
04/2012- 12/2012	A Randomized, Double-Blind Placebo Controlled, 4-Week trial of IMO-3100 in Patients with Moderate to Severe Plaque Psoriasis
04/2012-05/2014	Randomized, Double-Blind, Vehicle-Controlled, Multicenter, parallel-Group Clinical Trials to assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 weeks in Subjects with papulopustular Rosacea
05/2012-01/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Naftifine HCL Cream 1% to Naftin Cream 1% in the Treatment of Tinea Pedis
08/2012- 07/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Vehicle Controlled, Multicenter Study Comparing Imiquimod 3.75% to Zyclara
10/2012- 05/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac
10/2012- 07/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Diclofenac Sodium Gel 3% to Solaraze
08/2012-06/2014	A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose Escalating Study to Evaluate Coretexalone 17a-Propionate Once Daily or Twice Daily in Subjects with Facial Acne Vulgaris.
04/2013- 12/2013	A randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple Site, Clinical Study Comparing Diclofenac Sodium Gel 3% to Solaraze
02/2013-02/2013	A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris- Braintree
03/2013-09/2013	A Multicenter, Randomized, Double-Blind, Phase 3 Study of the Safety, Efficacy, Systemic Exposure, and Pharmacodynamics of Calcipotriene Foam, 0.005% Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) with Plaque Psoriasis
04/2013-04/2014	A Double-Blind, Randomized, Parallel-Group, Vehicle Controlled, Multicenter Study Comparing TOLMAR Azelaic Acid Gel, 15% to Reference Listed Drug in the Treatment of Rosacea
04/2013-06/2014	A Double-Blind, Randomized, Parallel Group, Vehicle-Controlled, Multicenter Study Comparing TOLMAR Naftifine HCl cream, 2% to Reference listed Drug in the treatment of Tinea Pedis

05/2013-09/2014	A randomized, Vehicle-Controlled, Double-blind, Parallel Group, Multi-center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects with Plaque Psoriasis
09/2013-02/2015	A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-controlled Study to Evaluate the Safety and Efficacy and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference listed Finacea Gel 15% in patients with Moderate Facial Rosacea
09/2013-02/2015	A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, and Efficacy Study of VPD-737 in the Treatment of Subjects with Chronic Pruritis
11/2013-02/2015	Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm ² on The Chest in Subjects with Actinic Keratosis
11/2013-08/2014	A Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara cream 2.5% in Subjects with Actinic Keratoses
11/2013-06/2015	A Randomized, Double-Blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2%/Benzoyl Peroxide 5% gel versus DUAC Gel versus Placebo in the ratio of 2:2:1 respectively in Patients with Acne Vulgaris
12/2013-12/2014	A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene Lotion 0.05% and the Efficacy of Bethamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis
02/2014-10/2014	A randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of An Anticholinergic Agent Agent for the Treatment of Primary Axillary Hyperhidrosis
02/2014-01/2015	A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris
02/2014-09/2014	A Randomized, Double-Blind, Multiple Site, Placebo-Controlled, Parallel Design Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo Topical Gel in the Treatment of Acne Vulgaris
05/2014-07/2015	A Phase 3 study of photodynamic therapy with Levulan Kerastick Topical solution + Blue light versus topical solution vehicle+ blue light for the treatments of actinic keratoses on the upper extremities
06/2014-02/2015	Efficacy and Safety of Oxymetazoline HCl Cream 1.0% for the Treatment of Persistent Erythema Associated with Rosacea
11/2014-05/2015	Safety and efficacy of escalating doses of LEO 43204 applied once daily for two consecutive days on approximately 250 cm ² on trunk and extremities in subjects with actinic keratosis

09/2014-09/2015	A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis Treated with Dupilumab
03/2012-12/2015	A Phase 3B, Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate a “Subject Tailored” Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis-PSTELLAR
05/2015-02/2016	A Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Three Concentrations of Topically Applied BBI-4000 gel in Subjects with Axillary Hyperhidrosis
05/2015-12/2015	A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% Compared to Solaraze 3%, gel in the Treatment of Actinic Keratosis
05/2015-12/2015	A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia (AGA)

Current Trials

3/2006 – Present	APPLES Trial, Phase IV Study of Protopic Ointment Safety and Outcomes in the Treatment of Atopic Dermatitis
9/2008- Present	Phase IV Study of Remicade Safety (PSOLAR)
12/2008-Present	Phase IV Study of Humira Safety for the Treatment of Plaque Psoriasis (ESPRIT Registry)
10/2012-Present	A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared with Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis
03/2013-Present	A 64-Week, Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects with moderate-to-Severe Chronic Plaque Psoriasis
12/2013-Present	IIF-MC-RHBA (b): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
03/2014-Present	RegiSONIC: A Prospective Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients
04/2014-Present	A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Chronic Plaque Psoriasis (CHS-0214-04) (RaPsOdy)

08/2014-Present	Twelve Month Follow-up Evaluation of Subjects Participating in Dusa-CP0108 (A Phase 3 Study of Photodynamic Therapy with Levulan® Kerastick® Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
02/2015-Present	A Phase 2 Study Comparing The Occurrence Of Actinic Keratoses On The Face In High-Risk Individuals After Cryotherapy + Photodynamic Therapy With Levulan® Topical Solution + Blue Light Versus Cryotherapy + Vehicle Topical Solution + Blue Light
11/2014-Present	A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
11/2014-Present	A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Incorporating Randomized Withdrawal and Retreatment
11/2014-Present	A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
11/2014-Present	A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris
11/2014-Present	A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
02/2015-Present	A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Foam 0.05% versus Vehicle Foam in Subjects with Plaque Psoriasis
02/2015-Present	A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis
02/2015-Present	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating The Efficacy and Safety Of Multiple Dupilumab Dose Regimens Administered As Monotherapy For Maintaining Treatment Response In Patients With Atopic Dermatitis
02/2015-Present	An Open-Label study of Dupilumab in Patients with Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials
02/2015-Present	A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study To Determine The Therapeutic Equivalence Of Generic Fluorouracil Cream, 0.5% And Carac® (Fluorouracil) Cream, 0.5% In Subjects With Actinic Keratoses

04/2015-Present	A Multicenter, Randomized, Double-Blind, Vehicle controlled, Parallel Group Comparison Study To Determine The Therapeutic Equivalence Of A Generic Ingenol Mebutate Gel, 0.05% And Picato® Gel, 0.05% In Subjects With Actinic Keratosis On The Trunk Or Extremities
03/2015-Present	An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (isotretinoin) Capsules Administered Without Food in Subjects With Severe Recalcitrant Nodular Acne
07/2015-Present	A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of DRM04 in Subjects with Axillary Hyperhidrosis
07/2015-Present	An Open-Label Study Assessing Long-Term Safety Of Drm04 In Subjects With Primary Axillary Hyperhidrosis
08/2015-Present	Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm ² on the Chest
08/2015-Present	A Double-Blind, Randomized, Parallel-Group, Active Control Study to Compare the Efficacy and Safety of CHS-1420 Drug Product Versus Humira® in Subjects With Chronic Plaque Psoriasis
08/2015-Present	A Double-blind, randomized, placebo-controlled study, Evaluating the efficacy and safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
08/2015-Present	A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients
12/2015-Present	A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
12/2015- Present	A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Access the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
12/2015-Present	A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects with Papulopustular Rosacea with a 4 Week Follow-up Period
02/2016-Present	A Phase 1b Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects with Moderate to Severe Plaque Psoriasis
02/2016-Present	A Phase 2, Multicenter, Evaluator-Blinded Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IPD-118 Lotion with Tazorac ® (tazarotene) Cream, 0.05% in the Treatment of Plaque Psoriasis

02/2016-Present

BI 655066 versus Ustekinumab and placebo comparators in a randomized double blind trial for Maintenance use in Moderate to severe plaque type psoriasis

02/2016-Present

BI 655066 versus placebo In a Multicenter randomized double-blind study in patients with Moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawal and re-treatment